Clinical Trials Logo

Primary Vascular Dysregulation clinical trials

View clinical trials related to Primary Vascular Dysregulation.

Filter by:
  • None
  • Page 1

NCT ID: NCT01201551 Completed - Clinical trials for Primary Vascular Dysregulation

Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature

Start date: June 2011
Phase: N/A
Study type: Interventional

It is already known that the local treatment with Alphagan eye drops (a drug commonly used by glaucoma patients) reduces ocular blood flow. In-vitro studies suggest that the vasoconstrictive effect of Alphagan is more pronounced when this drug is combined with a prostaglandin analogue (eg. Xalatan eye drops). The investigators also question whether this effect is more pronounced in subjects suffering from a primary vascular dysregulation (PVD). To test for the effect of these drugs on PVD and non-PVD subjects the investigators will take measurements of corneal temperature as surrogate for ocular blood flow.